Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance

Acta Biomaterialia

Volumn 11, Issue 1, 2015, Pages 368-380

  Zheng, Wenjing ^a   Cao, Chengwen ^a   Liu, Yanan ^b   Yu, Qianqian ^a   Zheng, Chuping ^a   Sun, Dongdong ^a   Ren, Xiaofan ^a   Liu, Jie ^a  

^a JINAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dual delivering; Multidrug resistance; Polyamidoamine; Selenium nanoparticles; Small interfering RNA

Indexed keywords

CELL DEATH; CELL SIGNALING; CONTROLLED DRUG DELIVERY; DETOXIFICATION; DISEASE CONTROL; DISEASES; GENE THERAPY; GLYCOPROTEINS; NANOPARTICLES; RNA; SELENIUM; SELENIUM COMPOUNDS; SYNTHESIS (CHEMICAL); TARGETED DRUG DELIVERY; TUMORS;

CHEMOTHERAPEUTIC AGENTS; CIS-PLATIN; CISPLATIN; DRUG-RESISTANCE; DUAL-DELIVERING; MULTIDRUG RESISTANCE; POLYAMIDOAMINES; SELENIUM NANOPARTICLES; SMALL INTERFERING RNA; TUMOUR CELLS;

CHEMOTHERAPY;

AMINE; CISPLATIN; DENDRIMER; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; POLYAMIDOAMINE; PROTEIN KINASE B; SELENIUM NANOPARTICLE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; METAL NANOPARTICLE; NANOCAPSULE; PAMAM STARBURST; SELENIUM;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATIC ELECTRICITY; ANIMAL; CHEMISTRY; DRUG RESISTANCE; GENETICS; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DENDRIMERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GENETIC THERAPY; HUMANS; METAL NANOPARTICLES; MICE; MICE, NUDE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; RNA, SMALL INTERFERING; SELENIUM; TREATMENT OUTCOME;

EID: 84924977521     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.08.035     Document Type: Article

References (45)

1. Teicher BA. Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol 2009;77:1665-73.
2. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
3. Ambudkar SV, Kim I-W, Booth-Genthe C. Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 2008;8:193-200.
4. Bhatia A, Schäfer H-J, Hrycyna CA. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry 2005;44:10893-904.
5. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159.
6. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005;52:609-27 [English edition].
7. Li J-M, Wang Y-Y, Zhao M-X, Tan C-P, Li Y-Q, Le X-Y, et al. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 2012;33:2780-90.
8. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539-50.
9. Sun D, Liu Y, Yu Q, Zhou Y, Zhang R, Chen X, et al. The effects of luminescent ruthenium (II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials 2012;34:171-80.
10. Sun D, Liu Y, Yu Q, Qin X, Yang L, Zhou Y, et al. Inhibition of tumor growth and vasculature and fluorescence imaging using functionalized ruthenium-thiol protected selenium nanoparticles. Biomaterials 2014;35:1572-83.
11. Wang H, Zhang J, Yu H. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: comparison with selenomethionine in mice. Free Radical Biol Med 2007;42:1524-33.
12. Zhang J, Wang X, Xu T. Elemental selenium at nano size (Nano-Se) as a potential chemopreventive agent with reduced risk of selenium toxicity: comparison with Se-methylselenocysteine in mice. Toxicol Sci 2008;101:22-31.
13. Jain K, Kesharwani P, Gupta U, Jain N. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010;394:122-42.
14. Nam HY, Nam K, Hahn HJ, Kim BH, Lim HJ, Kim HJ, et al. Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. Biomaterials 2009;30:665-73.
15. Lungwitz U, Breunig M, Blunk T, Göpferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005;60:247-66.
16. Cheng Y, Zhao L, Li Y, Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev 2011;40:2673-703.
17. Gabrielson NP, Pack DW. Acetylation of polyethylenimine enhances gene delivery via weakened polymer/DNA interactions. Biomacromolecules 2006;7:2427-35.
18. Santos JL, Oliveira H, Pandita D, Rodrigues J, Pêgo AP, Granja PL, et al. Functionalization of poly (amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J Control Release 2010;144:55-64.
19. Shakhbazau A, Isayenka I, Kartel N, Goncharova N, Seviaryn I, Kosmacheva S, et al. Transfection efficiencies of PAMAM dendrimers correlate inversely with their hydrophobicity. Int J Pharm 2010;383:228-35.
20. Fant K, Esbjörner EK, Jenkins A, Grossel MC, Lincoln P, Nordén B. Effects of PEGylation and acetylation of PAMAM dendrimers on DNA binding, cytotoxicity and in vitro transfection efficiency. Mol Pharm 2010;7:1734-46.
21. Qi R, Gao Y, Tang Y, He R-R, Liu T-L, He Y, et al. PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. AAPS J 2009;11:395-405.
22. He H, Li Y, Jia X-R, Du J, Ying X, Lu W-L, et al. PEGylated Poly (amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011;32:478-87.
23. Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Balian G, et al. Receptor-mediated gene delivery using PAMAM dendrimers conjugated with peptides recognized by mesenchymal stem cells. Mol Pharm 2010;7:763-74.
24. Han L, Zhang A, Wang H, Pu P, Jiang X, Kang C, et al. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 2010;21:417-26.
25. Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, et al. Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 2012;33:3025-35.
26. Babu VR, Mallikarjun V, Nikhat S, Srikanth G. Dendrimers: a new carrier system for drug delivery. Int J Pharm Appl Sci 2010;1:1-10.
27. Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005;30:294-324.
28. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-90.
29. Navarro G, Tros de ILarduya C. Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo. Nanomed Nanotechnol Biol Med 2009;5:287-97.
30. Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, Andresen TL. The possible "proton sponge" effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther 2012;21:149-57.
31. Wattiaux R, Laurent N, Wattiaux-De Coninck S, Jadot M. Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 2000;41:201-8.
32. Kakimoto S, Hamada T, Komatsu Y, Takagi M, Tanabe T, Azuma H, et al. The conjugation of diphtheria toxin T domain to poly (ethylenimine) based vectors for enhanced endosomal escape during gene transfection. Biomaterials 2009;30:402-8.
33. Mecke A, Lee DK, Ramamoorthy A, Orr BG, Holl MMB. Synthetic and natural polycationic polymer nanoparticles interact selectively with fluid-phase domains of DMPC lipid bilayers. Langmuir 2005;21:8588-90.
34. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011;50:161-78.
35. Longley D, Johnston P. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
36. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res/Fundam Mol Mech Mutagen 2001;478:23-43.
37. Min Y, Mao CQ, Chen S, Ma G, Wang J, Liu Y. Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angew Chem Int Ed 2012;51:6742-7.
38. Florea A-M, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011;3:1351-71.
39. Kostrhunova H, Kasparkova J, Gibson D, Brabec V. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione. Mol Pharm 2010;7:2093-102.
40. Knipp M, Karotki AV, Chesnov S, Natile G, Sadler PJ, Brabec V, et al. Reaction of Zn7Metallothionein with cis- and trans-[Pt (N-donor) 2Cl2] anticancer complexes: trans-PtII complexes retain their N-donor ligands. J Med Chem 2007;50:4075-86.
41. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-5.
42. Biliran H, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005;11:6075-86.
43. Kolch W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 2002;3:709-18.
44. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
45. Xiong L, Yang T, Yang Y, Xu C, Li F. Long-term in vivo biodistribution imaging and toxicity of polyacrylic acid-coated upconversion nanophosphors. Biomaterials 2010;31:7078-85.